Alembic Pharmaceuticals Receives USFDA Approval For Solifenacin Succinate Tablets

Alembic Pharmaceuticals Limited has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Solifenacin Succinate Tablets, 5 mg and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Vesicare Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc. Solifenacin Succinate Tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Solifenacin Succinate Tablets, 5 mg and 10 mg have an estimated market size of US$ 967 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 94 ANDA approvals (82 final approvals and 12 tentative approvals) from USFDA.

Shares of 20 MICRONS LTD. was last trading in BSE at Rs.36.4 as compared to the previous close of Rs. 33.5. The total number of shares traded during the day was 2048 in over 55 trades.

The stock hit an intraday high of Rs. 36.65 and intraday low of 35.2. The net turnover during the day was Rs. 73532. – Equity Bulls

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.